PAP-1 is a potent and selective small molecule inhibitor of the Kv1.3 potassium channel, exhibiting an EC50 of 2 nM and oral bioavailability. Its research applications include in vitro electrophysiology studies and in vivo models for investigating T cell-mediated autoimmune diseases, such as multiple sclerosis and type-1 diabetes.